Background: Advanced glycation end products (AGEs) play a pivotal role in various human pathologies, including aging and metabolic diseases, and their formation may have significant physiological consequences for human health. Fructoselysine (FL) is an intermediate in the formation of AGEs, and its accumulation has been associated with detrimental health effects. Although several chromatographic methods have been developed for AGEs detection and quantification, no mass spectrometry-based approach has previously been established to quantify FL in different human biological matrices. Methods: In this study, we present a novel UHPLC-HRMS/MS method for the identification and quantification of this compound in various biological matrices, including plasma, feces, and urine. Results: The method demonstrates excellent linearity, accuracy, and precision, with limit of detection (LOD) of 0.02 µM and limit of quantification (LOQ) of 0.06 µM. Recovery rates ranged from 95% to 109% and intra- and inter-day relative standard deviations (RSDs) were below 10%, indicating robust analytical performance. The validated method was successfully applied to quantify FL in plasma, feces, and urine samples from healthy individuals. Additionally, given the known association between AGEs and diabetes, we analyzed a small cohort of prediabetic patients and observed elevated circulating levels of FL compared to healthy controls. Conclusions: This study introduces a sensitive and reliable method for the specific detection and quantification of FL in biological samples and provides new insights into early molecular changes associated with prediabetic condition to improve early diagnosis in aging related diseases.
Fenizia et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: